

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number	10575592
Filing Date	2006-04-12
First Named Inventor	Kettie
Art Unit	1624
Examiner Name	Mark L. Berch
Attorney Docket Number	101250-1P US

U.S. PATENTS

[Remove](#)

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	3135753		1964-06-02	Hitchings et al.	
	2	4820709		1989-04-11	Hofer	
	3	5173491		1992-12-22	Kamoun et al.	
	4	5489598		1996-02-06	Connor et al.	
	5	5716967		1998-02-10	Kleinman	
	6	5756511		1998-05-26	West et al.	
	7	5976823		1999-11-02	Wu	
	8	6025361		2000-02-15	Cavalla et al.	

/Mark Berch/ (02/25/2009)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10575592
Filing Date	2006-04-12
First Named Inventor	Kettie
Art Unit	1624
Examiner Name	Mark L. Berch
Attorney Docket Number	101250-1P US

9	6046019		2000-04-04	Goumeniouk et al.	
10	6066641		2000-05-23	Cavalla et al.	
11	6294541		2001-09-25	Cavalla et al.	
12	6319928		2001-11-20	Chasin et al.	
13	7108997		2006-09-19	Kettie	

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS

Remove

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20040022871		2004-02-05	Mainnemare	
	2	20040029871		2004-02-12	Thong et al.	
	3	20050070558		2005-03-31	Vidal Juan et al.	
	4	20050234036		2005-10-20	Hanson et al.	

/Mark Berch/ (02/25/2009)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10575592
Filing Date	2006-04-12
First Named Inventor	Kettie
Art Unit	1624
Examiner Name	Mark L. Berch
Attorney Docket Number	101250-1P US

5	20070093483	2007-04-26	Svensson et al.
---	-------------	------------	-----------------

If you wish to add additional U.S. Published Application citation information please click the Add button. [Add](#)

FOREIGN PATENT DOCUMENTS

[Remove](#)

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	1013676	CN		1991-08-28	Euroceltique S.A.		<input checked="" type="checkbox"/>
	2	0010531	EP		1982-06-02	Aktiebolaget Draco Fack		<input type="checkbox"/>
	3	0359505	EP		1990-03-21	Smithkline Beecham Corporation		<input type="checkbox"/>
	4	0430300	EP		1991-06-05	Takeda Chemical Industries, Ltd		<input type="checkbox"/>
	5	0452926	EP		1996-03-13	Merrell Dow Pharmaceuticals Inc.		<input type="checkbox"/>
	6	01016407	EP		2006-05-10	Kyowa Hakko Kogyo Co., Ltd		<input type="checkbox"/>
	7	02160235	JP		1990-06-20	Konica Corp		<input type="checkbox"/>
	8	8906125	WO		1989-07-13	Smithkline Beckman Corporation		<input type="checkbox"/>

/Mark Berch/ (02/25/2009)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10575592
Filing Date		2006-04-12
First Named Inventor	Kettie	
Art Unit	1624	
Examiner Name	Mark L. Berch	
Attorney Docket Number	101250-1P US	

9	9500516	WO		1995-01-05	Euro-Celtique S.A.		<input type="checkbox"/>
10	9914204	WO		1999-03-25	G.D. Searle & Co.		<input type="checkbox"/>
11	9917773	WO		1999-04-15	Smithkline Beecham Corporation		<input type="checkbox"/>
12	9936073	WO		1999-07-22	Cell Therapeutics Inc.		<input type="checkbox"/>
13	9940091	WO		1999-08-12	Amgen Inc.		<input type="checkbox"/>
14	0051598	WO		2000-09-08	Smithkline Beecham Corporation		<input type="checkbox"/>
15	0059449	WO		2000-10-12	Euro-Celtique S.A.		<input type="checkbox"/>
16	0185146	WO		2001-11-15	AstraZeneca AB		<input type="checkbox"/>
17	02006272	WO		2002-01-24	Sanofi-Synthelabo		<input type="checkbox"/>
18	02066447	WO		2002-08-29	Ono Pharmaceutical Co., Ltd		<input type="checkbox"/>
19	02090575	WO		2002-11-14	AstraZeneca AB		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10575592
Filing Date		2006-04-12
First Named Inventor	Kettie	
Art Unit	1624	
Examiner Name	Mark L. Berch	
Attorney Docket Number	101250-1P US	

	20	03000694	WO		2003-01-03	Almirall Prodesfarma S. A.		<input type="checkbox"/>
	21	03082873	WO		2003-10-09	Almirall Prodesfarma S. A.		<input type="checkbox"/>
	22	2004096781	WO		2004-11-11	AstraZeneca AB		<input type="checkbox"/>
	23	2005042534	WO		2005-05-12	CV Therapeutics Inc.		<input type="checkbox"/>
	24	2005077950	WO		2005-08-25	Smithkline Beecham Corporation		<input type="checkbox"/>
	25	2006045564	WO		2006-05-04	Smithkline Beecham Corporation		<input type="checkbox"/>
	26	2006046910	WO		2006-05-04	AstraZeneca AB		<input type="checkbox"/>
	27	2006062465	WO		2006-06-15	AstraZeneca AB		<input type="checkbox"/>
	28	2007142576	WO		2007-12-13	AstraZeneca AB		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
--------------------	---------	---	----------------

/Mark Berch/ (02/25/2009)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10575592
Filing Date	2006-04-12
First Named Inventor	Kettie
Art Unit	1624
Examiner Name	Mark L. Berch
Attorney Docket Number	101250-1P US

1	AARON, S D et al., "Granulocyte Inflammatory Markers and Airway Infection during Acute Exacerbation of Chronic Obstructive Pulmonary Disease," Am J Respir Crit Care Med., 2001, pgs. 349-355, vol. 163	<input type="checkbox"/>
2	AKBIYIK et al., "In vitro and in vivo inhibition of myeloperoxidase with 5-fluorouracil," Eur. J. Clin. Pharmacol., 2001, Vol. 57, pgs. 631-636	<input type="checkbox"/>
3	ARMITAGE et al., "Structure-Activity Relationships in a Series of 6-Thioxanthines with Bronchodilator and Coronary Dilator Properties," British Journal of Pharmacology and Chemotherapy (1961), Vol. 17, pgs 196-207	<input type="checkbox"/>
4	BERLOW et al., "The Effect of Dapsone in Steroid-Dependent Asthma," 1991, J. Allergy Clin. Immunol., 1991, Vol. 87 (3), pgs. 710-715	<input type="checkbox"/>
5	BOZEMAN et al., "Inhibition of the human leukocyte enzymes myeloperoxidase and eosinophil peroxidase by dapsone," Biochemical Pharmacology, 1992, Vol. 44, No. 3, pgs. 553-563	<input type="checkbox"/>
6	DALLEGRI et al., "Possible Modes of Action of Nimesulide in Controlling Neutrophilic Inflammation," Arzneimittel-Forschung/Drug Research, 1995, Vol. 45(II), No. 10, pgs. 1114-1117	<input type="checkbox"/>
7	GARST et al., "Inhibition of Separated Forms of Phosphodiesterases from Pig Coronary Arteries by Uracils and by 7-Substituted Derivatives of 1-Methyl-3-isobutylxanthine," J. Med. Chem.; 1976; Vol. 19(4) pgs 499-503	<input type="checkbox"/>
8	GRISHAM et al., "Assessment of Leukocyte involvement during Ischemia and Reperfusion of Intestine," Am. J. Physiol., 1986, Vol. 251, pgs. 729-743	<input type="checkbox"/>
9	HOPE et al., "Large scale purification of myeloperoxidase from HL60 promyelocytic cells: characterization and comparison to human neutrophil myeloperoxidase," Protein Expression and Purification, 2000, Vol. 18, pgs. 269-276	<input type="checkbox"/>
10	IMAI et al., "Studies on Nucleic Acid Antagonists. VII. Synthesis and Characterization of 1,4,6-Triazaindenes (5H-Pyrrolo(3,2-d)pyrimidines)" Chem. Pharm. Bull., 1964, Vol. 12, No. 9, pgs. 1030-1042	<input type="checkbox"/>
11	JACOBSON et al., "1,3-Dialkylxanthine Derivatives Having High Potency as Antagonists at Human A2B Adenosine Receptors," Drug Development Research, 1999, Vol. 47, pgs 45-53	<input type="checkbox"/>

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10575592
Filing Date	2006-04-12
First Named Inventor	Kettie
Art Unit	1624
Examiner Name	Mark L. Berch
Attorney Docket Number	101250-1P US

12	KETTLE et al., "Assays for the Chlorination Activity of Myeloperoxidase," Biophyl, 1992, Vol. 296, pgs. 502-513	<input type="checkbox"/>
13	KETTLE et al., "Mechanism of inhibition of myeloperoxidase by anti-inflammatory drugs," Biochemical Pharmacology, 1991, Vol. 41, No. 10, pgs. 1485-1492	<input type="checkbox"/>
14	KETTLE et al., "Superoxide is an Antagonist of Anti-Inflammatory Drugs that Inhibit Hypochlorous Acid Production by Myeloperoxidase," Biochemical Pharmacology, 1993, Vol. 45, No. 10, pgs. 2003-2010	<input type="checkbox"/>
15	Khimicheskaya encyclopedia, ed. by Knunyants I.L., "Sovetskaya encyclopedia", 1990, V. 2, pg. 1083	<input checked="" type="checkbox"/>
16	NOCKER et al., "Interleukin-8 in Airway Inflammation in Patients with Chronic Asthma and Chronic Obstructive Pulmonary Disease," Int. Arch Allergy Immunol., 1996, Vol. 109, pgs. 183-191	<input type="checkbox"/>
17	OTTONELLO et al., "Sulphonamides as Anti-Inflammatory Agents: Old Drugs for New Therapeutic Strategies in Neutrophilic Inflammation," Clinical Science, 1995, Vol. 88, pgs. 331-336	<input type="checkbox"/>
18	RAO et al., "Synthesis of 5,7-Disubstituted-4-Beta-D-ribofuranosylpyrazolo[4,3-d]-pyrimidines and 2,4-Disubstituted-1-Beta-D-ribofuranosylpyrrolo[3,2-d]-pyrimidines as Congeners of Uridine and Cytidine," J. Heterocyclic Chemistry, 1992, Vol. 29, pgs 343-354	<input type="checkbox"/>
19	SUZUKI et al., "Assay method for myeloperoxidase in human polymorphonuclear leukocytes," Analytical Biochemistry, 1983, Vol. 132, pgs. 345-352	<input type="checkbox"/>
20	VAN GALEN et al., "A Binding Site Model and Structure-Activity Relationships for the Rat A3 Adenosine Receptor," Molecular Pharmacology, 1994, Vol. 45, pgs 1101-1111	<input type="checkbox"/>
21	WOO et al., "Inhibitors of Human Purine Nucleoside Phosphorylase. Synthesis and Biological Activities of 8-Amino-3-benzylhypoxanthine and Related Analogues," J. Med. Chem., 1992; Vol. 35, pgs 1451-1457	<input type="checkbox"/>
22	WOOLDRIDGE et al., "The Synthesis of Some 6-Thioxanthines," J. Chem. Soc., 1962, pgs 1863-1868	<input type="checkbox"/>

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10575592
Filing Date	2006-04-12
First Named Inventor	Kettie
Art Unit	1624
Examiner Name	Mark L. Berch
Attorney Docket Number	101250-1P US

23	STN printout for Registry No. 582-33-2: 3-Aminobenzoic acid ethyl ester	<input type="checkbox"/>
24	STN Intl, Registry No. 2487-40-3	<input type="checkbox"/>
25	English abstract for JP 02160235	<input type="checkbox"/>
26	English abstract for WO 2002006272	<input type="checkbox"/>
27	Copy of non-final OA issued for 10/511537 on April 27, 2007, AstraZeneca Ref. 100647	<input type="checkbox"/>
28	Copy of OA issued for 10/511537 on August 27, 2007, AstraZeneca Ref. 100647	<input type="checkbox"/>
29	Copy of non-final OA issued for 10/476999 on October 31, 2005, AstraZeneca Ref. 100553	<input type="checkbox"/>
30	Copy of Advisory Action issued for 10/275824 on May 22, 2007, AstraZeneca Ref. 100046	<input type="checkbox"/>
31	Copy of final OA issued for 10/275824 on February 8, 2007, AstraZeneca Ref. 100046	<input type="checkbox"/>
32	Copy of non-final OA issued for 10/275824 on June 19, 2006, AstraZeneca Ref. 100046	<input type="checkbox"/>
33	Copy of Advisory Action issued for 10/275824 on March 15, 2006, AstraZeneca Ref. 100046	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10575592
Filing Date	2006-04-12
First Named Inventor	Kettie
Art Unit	1624
Examiner Name	Mark L. Berch
Attorney Docket Number	101250-1P US

34	Copy of final OA issued for 10/275824 on November 30, 2005, AstraZeneca Ref. 100046	<input type="checkbox"/>
35	Copy of non-final OA issued for 10/275824 on June 17, 2005, AstraZeneca Ref. 100046	<input type="checkbox"/>
36	U.S. Application Serial No. 11/577833, Attorney Docket No. 101584-1P US, filed on April 24, 2007	<input type="checkbox"/>
37	U.S. Application Serial No. 11/720913, Attorney Docket No. 101621-1P US, filed on June 5, 2007	<input type="checkbox"/>
38	U.S. Application Serial No. 11/756967, Attorney Docket No. 102288-2 US, filed on June 1, 2007	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Mark Berch/ (02/25/2009)	Date Considered	
--------------------	---------------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.